Developing treatments to turn back the 'cellular clock'

老龄化是一种普遍现象，也是人类最常见的慢性疾病的主要风险因素。我们的公司SENISCA是从埃克塞特大学剥离出来的，最初专注于开发适合治疗皮肤老化的分子，然后是更广泛的愿景，为与年龄相关的疾病提供创新、有效的药物治疗。衰老发生在细胞和组织水平，因为一些基本的健康维护机制失败。导致SENISCA受专利保护的创新的研究发现了一种新的衰老分子机制，可以用于细胞再生。SENISCA的现有数据表明，衰老细胞的再生是可能的，这带来了开发治疗任何与年龄相关的疾病或带有衰老成分的疾病的可能性。该项目将侧重于确定天然存在的或FDA批准的具有抗衰老特性的化合物的组合，并获得主要的安全性和毒性数据，为向皮肤老化市场发放许可证做准备。

Ageing is a universal phenomenon and the primary risk factor for most common, chronic human diseases. Our company, SENISCA, is a spin-out from the University of Exeter, initially focussing on developing molecules suitable for treatment of skin ageing, followed by a wider vision to deliver innovative, effective pharmaceutical treatments for age-related diseases.Ageing occurs at the cell and tissue level because of failure of a few basic health maintenance mechanisms. The research leading to SENISCA's patent-protected innovation has identified a novel molecular mechanism of ageing that can be manipulated for cellular rejuvenation.SENISCA's existing data, showing that rejuvenation of senescent cells is possible, gives rise to the possibility of developing treatments for any age-related disease or condition with a senescence component. This project will focus on identifying combinations of naturally occurring or FDA-approved compounds with anti-ageing properties and obtaining primary safety and toxicity data in preparation for out-licensing to the skin ageing market.